|Day Low/High||97.53 / 98.26|
|52 Wk Low/High||92.09 / 116.40|
Immunoglobulin Leader Donates €15,000 to International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives
Carlisle Companies Incorporated (NYSE:CSL) is celebrating the 100 th anniversary of its founding in September 2017.
- Builds on CSL Behring's promise to patients with rare and serious diseases
Steven J. Ford, Vice President of Investor Relations, Secretary & General Counsel of Carlisle Companies Incorporated (NYSE:CSL), will be presenting at the Jefferies 2017 Industrials Conference in New York City, NY on...
The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a 6% increase in the Company's regular quarterly dividend, to $0.
Carlisle Companies Incorporated (NYSE:CSL) reported record net sales of $1,071.
First and only subcutaneous preventive treatment option reduced HAE attacks by 95 percent (median) in treated patients
FDA grants seven-year marketing exclusivity for subcutaneous C1-INH to prevent HAE attacks
Application based on data from the largest-ever randomized CIDP trial
Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...
Findings presented at the International Society on Thrombosis and Haemostasis Congress 2017 show product's impact on treatment adherence, consumption and quality of life
CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards
Results of study, which compared AFSTYLA to octocog alfa, were presented at the International Society on Thrombosis and Haemostasis Congress 2017
New findings demonstrate CSL Behring's promise to develop and deliver innovative treatments that improve patients' lives
Carlisle Companies Incorporated (NYSE:CSL) today announced the acquisition of Drexel Metals, Inc.
Carlisle Companies Incorporated (NYSE:CSL) will release second quarter 2017 results on Tuesday, July 25, 2017 after the market closes.
- Use of rescue medication was reduced by greater than 99 percent1
Driven by its promise to save lives and protect people's health, CSL Behring is honoured to be recognized by NORD, a tireless advocate for rare disease patients.
Carlisle Companies Incorporated (NYSE:CSL) reported net sales of $857.
The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a regular quarterly dividend of $0.
- AFSTYLA is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A
- CSL Behring Marks World Hemophilia Day by Donating IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia
CSL Behring Sponsors the First Network of its Kind on the African Continent
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.